



Anatara Lifesciences strengthens team with new appointments

MELBOURNE, 6 December 2021: Anatara Lifesciences (ASX: ANR) is pleased to announce the appointment of Mr Simon Erskine as Chief Development Officer and Mr Michael Pryor as Head of Business Development & Marketing Communications, to progress the Company's commercialisation activities in the gastrointestinal health space.

Chief Development Officer – Simon Erskine

Mr Erskine joined Anatara with more than ten years' experience working within the biotechnology, IVD (in vitro diagnostic) medical devices and molecular diagnostics industries. He has held numerous research and development roles including product and clinical development, regulatory affairs and quality assurance, and has successfully translated early-stage research into commercial products for the Australian, European, Canadian and US markets.

Mr Erskine has overseen global teams and partnerships of rapid growth biotech start-ups, including senior roles at Genetic Signatures and SpeedX. His broad history of accomplishments across test development, laboratory procedures, quality and resource optimisation, human research and clinical studies will be pivotal to Anatara's work towards commercialisation of the Company's GaRP pipeline.

Head of Business Development & Marketing Communications – Michael Pryor

Mr Pryor is a marketing executive with 20 years' experience in the Australian pharmaceutical industry across marketing, sales and key account management. His experience spans the channels of pharmacy, optometry and grocery, where he has held various sales and marketing roles with multinational companies.

Mr Pryor's most recent role was Commercial Manager (ANZ) at MENARINI Group where he led a highly successful team, driving sales, market share and profit growth within the pharmacy channel. Mr Pryor has developed an intimate understanding of the Australian pharmacy channel and has worked across a wide range of therapeutic areas, including gut health.

Commenting on the key appointments, Chief Executive Officer Steve Lydeamore, said: "I am very pleased to welcome Simon and Michael to Anatara's management team. Both bring extensive industry experience and are highly regarded in their respective fields, and will play a key role in supporting the commercialisation of Anatara's products.

"Simon and Michael will help drive the broadening of Anatara's gastrointestinal health market offerings to address the significant unmet need for evidence-based solutions and advice. This is a key part of our strategy to expand Anatara's position and profile as an emerging leader in evidence-based gut health solutions. I am looking forward to Simon and Michael's contribution to Anatara's growth."

Anatara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anatara.com | Website anataralifesciences.com



For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anataro Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataro.com	Eric Kuret Market Eye +61 (0) 417 311 335 eric.kuret@marketeye.com.au

About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for human and animal health. Anataro is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataro Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anataro Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anataro.com | **Website** anatarolifesciences.com

